Zhen Huang
Director/Board Member bij WALVAX BIOTECHNOLOGY CO., LTD.
Vermogen: 66 M $ op 31-03-2024
Profiel
Zhen Huang currently works at Walvax Biotechnology Co., Ltd., as Vice Chairman from 2019, Shanghai Zerun Biotechnology Co., Ltd., as Director, and Yuxi Walvax Biotechnology Co., Ltd., as President.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 30-06-2023 | 17 698 729 ( 1.14% ) | 38 M $ | 31-03-2024 | |
| 30-09-2023 | 13 274 047 ( 28.09% ) | 28 M $ | 31-03-2024 |
Actieve functies van Zhen Huang
| Bedrijven | Functie | Begin |
|---|---|---|
| WALVAX BIOTECHNOLOGY CO., LTD. | Director/Board Member | 22-08-2019 |
| Yuxi Walvax Biotechnology Co., Ltd. | President | - |
Shanghai Zerun Biotechnology Co., Ltd.
 Shanghai Zerun Biotechnology Co., Ltd. BiotechnologyHealth Technology Shanghai Zerun Biotechnology Co., Ltd. engages in the development, commercialization, and industrialization of new recombinant human vaccine products. It develops recombinant vaccines such as preventive cervical cancer vaccines, and recombinant enterovirus 71 virus-like particle and therapeutic vaccines. The company was founded on May 7, 2003 and is headquartered in Shanghai, China. | Director/Board Member | - |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| WALVAX BIOTECHNOLOGY CO., LTD. | Health Technology |
| Bedrijven in privébezit | 2 |
|---|---|
| Yuxi Walvax Biotechnology Co., Ltd. | |
Shanghai Zerun Biotechnology Co., Ltd.
Shanghai Zerun Biotechnology Co., Ltd. BiotechnologyHealth Technology Shanghai Zerun Biotechnology Co., Ltd. engages in the development, commercialization, and industrialization of new recombinant human vaccine products. It develops recombinant vaccines such as preventive cervical cancer vaccines, and recombinant enterovirus 71 virus-like particle and therapeutic vaccines. The company was founded on May 7, 2003 and is headquartered in Shanghai, China. | Health Technology |
